Microsoft (NASDAQ:MSFT) received a bullish endorsement from Wedbush on Thursday, with analyst Daniel Ives lifting the tech giant's price target to $600 from $515, citing accelerating adoption of ...

The artificial intelligence-based assay relies on images from an H&E stained biopsy slide and a machine learning model to determine risk of metastasis.